daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma
- DOI
- 10.1016/j.esmoop.2026.108621
- Published
- 2026-11
- Container
- ESMO Open
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmoop.2026.108621,
title = {daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma},
author = {S. Paulson and M. Ikeda and L. Shen and A. Stein and T. Macarulla and M. Milella and T. Golan and Z. Wainberg and J. Taieb and L. Wang and F. Polydoros and C. Abecunas and E. López and E.M. O’Reilly},
year = {2026},
journal = {ESMO Open},
doi = {10.1016/j.esmoop.2026.108621},
url = {https://doi.org/10.1016/j.esmoop.2026.108621}
}RIS
TY - JOUR TI - daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma AU - S. Paulson AU - M. Ikeda AU - L. Shen AU - A. Stein AU - T. Macarulla AU - M. Milella AU - T. Golan AU - Z. Wainberg AU - J. Taieb AU - L. Wang AU - F. Polydoros AU - C. Abecunas AU - E. López AU - E.M. O’Reilly PY - 2026 JO - ESMO Open DO - 10.1016/j.esmoop.2026.108621 UR - https://doi.org/10.1016/j.esmoop.2026.108621 ER -
APA
Paulson, S., Ikeda, M., Shen, L., Stein, A., Macarulla, T., Milella, M., Golan, T., Wainberg, Z., Taieb, J., Wang, L., Polydoros, F., Abecunas, C., López, E., & O’Reilly, E. (2026). daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma. ESMO Open. https://doi.org/10.1016/j.esmoop.2026.108621
Source records
- crossref · retrieved 2026-11-10T09:00:32.613Z